Outlook on the KRAS Inhibitors Global Market, Drug Price, Sales, & Clinical Trials Insight to 2029
08 févr. 2023 07h38 HE
|
Research and Markets
Dublin, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The "Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's...
Global AI-based Clinical Trials Solution Provider Market Report 2022: Better Operational Efficacy and Quicker Turnaround Times Driving Growth
07 nov. 2022 07h43 HE
|
Research and Markets
Dublin, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The "Global AI-based Clinical Trials Solution Provider Market Size, Share & Trends Analysis Report by Therapeutic Application, by Clinical Trial Phase,...
Outlook on the KRAS Inhibitors Global Market to 2028 - Key Drivers and Challenges
27 avr. 2022 05h28 HE
|
Research and Markets
Dublin, April 27, 2022 (GLOBE NEWSWIRE) -- The "Global KRAS Inhibitors Market & Clinical Trials Forecast 2028" report has been added to ResearchAndMarkets.com's offering. The advancement in...
Arch Biopartners Obtains DTC Eligibility for its Common Shares on OTCQB
21 août 2020 08h00 HE
|
Arch Biopartners
TORONTO, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced it has obtained eligibility with The Depository Trust...
FDA Grants Arch Biopartners Permission to Proceed with Phase II trial to Evaluate Metablok (LSALT peptide) for the Treatment of COVID-19 patients
16 juin 2020 10h48 HE
|
Arch Biopartners
International, multi-center, randomized, double-blind, placebo-controlled clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in...
Arch Biopartners Announces FDA Acknowledgement of its Investigational New Drug Application for Metablok (LSALT peptide)
15 juin 2020 08h19 HE
|
Arch Biopartners
International, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in...
Arch Biopartners Submits Investigational New Drug Application to the FDA for Metablok (LSALT peptide)
08 juin 2020 07h00 HE
|
Arch Biopartners
TORONTO, June 08, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Arch Biopartners Releases New Video Showing Metablok Reducing Lung Inflammation in an Animal Model
31 mars 2020 07h36 HE
|
Arch Biopartners
TORONTO, March 31, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...
ARCH BIOPARTNERS DISCLOSES NEW PATENT FILING FOR NOVEL DRUG CANDIDATES TO PREVENT LUNG INFLAMMATION
24 mars 2020 07h27 HE
|
Arch Biopartners
TORONTO, March 24, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...
Algernon Pharmaceuticals Appoints Novotech as CRO for First Phase 2 Trial and Announces Novotech’s $220K Equity Investment
17 janv. 2020 06h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Jan. 17, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...